ETFs with the most upside to analyst targets: Vanguard Russell 3000 ETF, Aardvark Therapeutics Inc, Ispire Technology Inc, and AlTi Global Inc.

The Vanguard Russell 3000 ETF (VTHR) has an implied analyst target price of $294.51 per unit, suggesting 13.53% upside from its recent price of $259.42. Three underlying holdings with notable upside are Aardvark Therapeutics (AARD), Ispire Technology (ISPR), and AlTi Global (ALTI), with average analyst target prices of $31.25, $7.50, and $9.00, respectively.

Analysts have set an implied target price of $294.51 per unit for the Vanguard Russell 3000 ETF (VTHR), suggesting a 13.53% upside from its recent price of $259.42 [1]. This target is based on the average analyst 12-month forward target price of the ETF's underlying holdings. Three key holdings within the ETF—Aardvark Therapeutics (AARD), Ispire Technology (ISPR), and AlTi Global (ALTI)—show significant potential for growth.

Aardvark Therapeutics (AARD) has an average analyst target price of $31.25, indicating a 19.08% upside from its recent price of $6.87 [2]. This optimism is supported by the stock's recent performance, which has seen a 3.97% gain on the last trading day and a 0.69% increase over the past two weeks [3]. However, the stock's high volatility and low trading volume make it a high-risk investment.

Ispire Technology (ISPR) has an average analyst target price of $7.50, reflecting an 18.20% upside from its recent price of $15.64 [2]. Roth Capital recently decreased its earnings estimates for Ispire Technology, but the stock has shown resilience, trading up 0.4% on May 19, 2025 [4]. The company's share repurchase program, which allows for the purchase of up to 4% of its shares, suggests that the company's leadership believes its stock is undervalued.

AlTi Global (ALTI) has an average analyst target price of $9.00, indicating a 18.46% upside from its recent price of $6.50 [2]. The stock's potential growth is supported by its recent performance, which has seen a 18.46% increase in its analyst target price.

Analysts' targets for these stocks and the Vanguard Russell 3000 ETF suggest a potential for growth in the near future. However, investors should conduct further research to determine if these targets are justified or if they reflect optimism that may not be supported by recent company and industry developments.

References:
[1] https://finance.yahoo.com/quote/VTHR/
[2] https://www.nasdaq.com/articles/analysts-expect-vbr-hit-222
[3] https://stockinvest.us/stock/AARD
[4] https://www.marketbeat.com/instant-alerts/roth-capital-analysts-decrease-earnings-estimates-for-ispr-2025-05-19/